REGENEREX PHARMA, INC.: 10-Q filed 2011-10-13

Name: REGENEREX PHARMA, INC.: 10-Q filed 2011-10-13
Creator: REGENEREX PHARMA, INC.

What REGENEREX PHARMA, INC. reported in its quarterly report filed 2011-10-13 (fiscal Q3 2011): 18 published measures, 53 facts as tagged in accession 0001072588-11-000208.

This filing

Form: 10-Q (quarterly report)
Filed: 2011-10-13
Fiscal period: fiscal Q3 2011
Accession: 0001072588-11-000208 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All REGENEREX PHARMA, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2011-08-31	377,122	USD
At 2010-11-30	6,290	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2011-08-31	339,076	USD
At 2010-11-30	-22,843	USD
At 2010-08-31	-13,817	USD
At 2009-11-30	-8,474	USD
At 2008-11-29	-2,526	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2011-08-31	698	USD
At 2010-11-30	6,090	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2010-12-01 to 2011-08-31	26,951	USD	274
2010-06-26 to 2011-08-31	53,290	USD	432
2009-12-01 to 2010-08-31	21,350	USD	274

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2010-12-01 to 2011-08-31	-19,261	USD	274
2010-06-26 to 2011-08-31	-30,707	USD	432
2009-12-01 to 2010-08-31	-14,363	USD	274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2010-12-01 to 2011-08-31	389,202	USD	274
2010-06-26 to 2011-08-31	402,202	USD	432
2009-12-01 to 2010-08-31	16,000	USD	274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2010-12-01 to 2011-08-31	-375,000	USD	274
2010-06-26 to 2011-08-31	-375,000	USD	432

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2011-08-31	-105,837	USD
At 2010-11-30	-105,837	USD

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

Period	Value	Unit	Days
2011-06-01 to 2011-08-31	102,521,739	shares	92
2010-12-01 to 2011-08-31	98,189,781	shares	274
2010-06-01 to 2010-08-31	216,000,000	shares	92
2009-12-01 to 2010-08-31	141,547,445	shares	274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2011-06-01 to 2011-08-31	-16,048	USD	92
2010-12-01 to 2011-08-31	-27,284	USD	274
2010-06-26 to 2011-08-31	-53,623	USD	432
2010-06-01 to 2010-08-31	-17,843	USD	92
2009-12-01 to 2010-08-31	-25,221	USD	274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2011-08-31	2,122	USD
At 2010-11-30	6,290	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2011-08-31	38,046	USD
At 2010-11-30	29,133	USD

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2011-08-31	171,000	shares
At 2010-11-30	96,000	shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2011-08-31	327,202	USD
At 2010-11-30	13,000	USD

Accumulated other comprehensive income or loss

Cumulative other comprehensive items after tax, such as translation and unrealized hedging or securities effects. These amounts have not passed through net income.

Period	Value	Unit	Days
At 2010-11-30	333	USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

Period	Value	Unit	Days
2011-06-01 to 2011-08-31	16,048	USD	92
2010-12-01 to 2011-08-31	27,284	USD	274
2010-06-26 to 2011-08-31	53,623	USD	432
2010-06-01 to 2010-08-31	17,877	USD	92
2009-12-01 to 2010-08-31	21,343	USD	274

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2011-06-01 to 2011-08-31	197	USD	92
2010-12-01 to 2011-08-31	764	USD	274
2010-06-26 to 2011-08-31	3,044	USD	432
2010-06-01 to 2010-08-31	1,231	USD	92
2009-12-01 to 2010-08-31	1,356	USD	274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2010-12-01 to 2011-08-31	-5,059	USD	274
2010-06-26 to 2011-08-31	-3,505	USD	432
2009-12-01 to 2010-08-31	1,637	USD	274

Inspect the source

Entity: REGENEREX PHARMA, INC. / CIK 0001357878
Captured: 2026-09-21T17:18:44.819Z
SEC response SHA-256: 213194c506fa9441e1992f90b01cc25fc346a1dd3e1f77e4d19752e41180a033

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001357878.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))